Parkinson's Disease Patients Get Long-Term Benefits From Experimental Gene Therapy
Collaboration partners, Neurocrine Biosciences (NASDAQ: NBIX) and Voyager Therapeutics (NASDAQ: VYGR) announced data from an early stage clinical trial with Parkinson's disease patients and NBIb-1817, an experimental gene therapy. Three years after a single administration, 14 out of 15 patients are still reporting motor function improvements.
At the moment, NBIb-1817 is in the middle of a phase 2 study that was put on hold in April due to the COVID-19 pandemic. If allowed to restart, the phase 2 RESTORE-1 trial will randomize patients to receive NBIb-1817 or a placebo, then measure for a change in "On" time without troublesome dyskinesia.
Image source: Getty Images.
Source Fool.com
